Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx Inc.
WKN: A116X0 / Name: Ardelyx / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
4,68 €
0,54 %
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Key Points
- Interested in Ardelyx, Inc.? Here are five stocks we like better.
- Ardelyx said its two commercial products, IBSRELA and XPHOZAH, are on track to generate more than $500 million in
Over the last few years, I have compared many sportsbooks by looking at odds, promotions, game variety, and withdrawal processing times. Among the platforms available to users in India, 1 Win often stands out for its extensive selection of betting opportunities. The betting sites IN category is highly competitive, but I appreciate that this platform combines a comprehensive sportsbook with a large casino section. There are hundreds of slot titles, live dealer tables, and regular bonus offers that keep things interesting. The interface is easy to navigate, making it simple to switch between sports betting and casino entertainment whenever I want.
Neueste Beiträge
meoowu77 in Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious